Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.

doi:10.1038/s41467-023-38195-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.

Nature communications - 5 May 2023

Berko Esther R, Witek Gabriela M, Matkar Smita, Petrova Zaritza O, Wu Megan A, Smith Courtney M, Daniels Alex, Kalna Joshua, Kennedy Annie, Gostuski Ivan, Casey Colleen, Krytska Kateryna, Gerelus Mark, Pavlick Dean, Ghazarian Susan, Park Julie R, Marachelian Araz, Maris John M, Goldsmith Kelly C, Radhakrishnan Ravi, Lemmon Mark A, Mossé Yaël P

Abstract excerpt

Activating point mutations in Anaplastic Lymphoma Kinase (ALK) have positioned ALK as the only mutated oncogene tractable for targeted therapy in neuroblastoma. Cells with these mutations respond to lorlatinib in pre-clinical studies, providing the rationale for a first-in-child Phase 1 trial (NCT03107988) in patients with ALK-driven neuroblastoma. To track evolutionary dynamics and heterogeneity of tumors, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anaplastic Lymphoma Kinase

Share to Carcinoma, Non-Small-Cell Lung

Share to Circulating Tumor DNA

Share to Drug Resistance, Neoplasm

Share to Lactams, Macrocyclic

Share to Neuroblastoma

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 37147298
DOI: 10.1038/s41467-023-38195-0
PMCID: PMC10163008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.PMID 37147298Read ↗

Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.Semantic proximity Read ↗

NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.Semantic proximity Read ↗

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNASemantic proximity Read ↗

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.Semantic proximity Read ↗

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation DiversitySemantic proximity Read ↗

Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patientsSemantic proximity Read ↗

Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.Semantic proximity Read ↗

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.Semantic proximity Read ↗

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.Semantic proximity Read ↗

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysisSemantic proximity Read ↗

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung CancerSemantic proximity Read ↗

Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.